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~70−90% within minutes when CK2 is inhibited by its speciﬁc inhibitor (TBB, n=8,
p< 0.001) but this WT inhibition disappears when a TBB-resistant CK2 mutant is
co-expressed with WT CFTR in oocytes (n=20, p< 0.001). Single channel analysis
shows similar results in mammalian cells where TBB CK2-inhibitor closes CFTR in
cell attached (but not detached) mode consistent with a protein–protein interaction in
cell attached (but not detached) patches. The missing link to inﬂammation manifests
when NFkB elevation in Hela cells stably expressing CFTR is found to be CK2
dependent in WT- but not DF508-CFTR expressing cell lines when exposed to Ps.
aeruginosa.
Conclusion: The data (Treharne et al 2007) are consistent with the idea that F508
is required for CK2 localisation to CFTR. A new collaboration funded by the
Italian CF Society with LA Pinna (Padua) is now shedding light on the mechanisms
involved leading to a new paradigm linking inﬂammation and ion transport in CF
due to malfunction of the CK2-DF508-CFTR interaction such that CK2 activity is
missing in the CF apical membrane.
Speculation: The ﬁnding that CFTR binds a known cancer inducing protein kinase
CK2 that targets another CFTR-bound cancer kinase (NDPK) whose function may
be abnormal in CF might explain the rising incidence of cancer in CF.
Supported by the Wellcome Trust, CF Trust and DFG.
R14 ROLE OF CFTR IN BILE SECRETION
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In the liver, CFTR is selectively expressed by bile duct epithelium where it promotes
the transmembrane efﬂux of Cl− and bicarbonate. The biliary epithelium is the site
of rapid hormone-mediated regulation of the ﬂuidity and alkalinity of the primary
canalicular bile secreted by the hepatocytes. The net amount of ﬂuid and bicarbonate
secreted is determined by the integration of pro-secretory and anti-secretory signals.
Biliary epithelial cells (cholangiocytes) possess a polarized distribution of carriers
that mediate vectorial HCO−3 and ﬂuid secretion, under the endocrine control of
secretin/cAMP/PKA on the basolateral side and under the autocrine control of
extracellular ATP/P2Y-receptors/intracellular Ca2+ on the apical side. In cholangio-
cytes CFTR has multiple functions, including: (a) mediating cAMP-dependent Cl−
secretion in response to cAMP/PKA, (b) regulating the activity of the apical Na+/H+
and Cl−/HCO−3 exchangers, (c) modulating vesicle-mediated ﬂuid and electrolyte
transport, (d) facilitating the apical release of ATP. We have recently shown that
UDCA stimulates apical ATP secretion in a CFTR-dependent manner. Apical ATP,
thereby activating Ca2+-dependent Cl− channels, is then responsible for UDCA-
induced ductal choleresis. This is a novel mechanism with important implications
for the treatment of CF-related liver disease. In this regard it is important to consider
that CFTR-independent ﬂuid secretory pathways are also present in cholangiocytes.
We have recently shown that the sulphonylurea glibenclamide (GL) stimulates
vesicle-mediated secretion in bile ducts in a CFTR-independent manner. This effect
is maintained in CFTR-KO mice, in which GL is able to restores choleresis. Whether
these promising ﬁndings will be translated into CF treatment strategies is at present
unclear. The only liver-speciﬁc therapy for CF proposed to date is the use of ur-
sodeoxycholic acid (UDCA). Administration of UDCA slows the progression of the
disease in humans, however, the choleretic effect of UDCA on biliary cells depends
on its ability to stimulate a CFTR-dependent ATP secretion, suggesting that its
pharmacologic mechanisms in CF is different form stimulation of ductal choleresis.
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It has been suggested that modest increases in CFTR function (in the range of
5%) may be sufﬁcient to ameliorate lung disease severity. Although generally less
efﬁcient than viral vectors, we hypothesize that the transfection efﬁciency of the
best non-viral gene transfer agents may be sufﬁcient for clinical beneﬁt. In a large
pre-clinical study we have compared a number of non-viral gene transfer agents
and have chosen cationic lipid GL67 as our leading Wave 1 product. GL67 will
be complexed to a plasmid carrying the CFTR gene, which has been signiﬁcantly
improved compared to plasmids used in previous clinical trials. The plasmid has
been completely CpG-depleted to minimise inﬂammatory responses to the DNA and
importantly a promoter has been chosen that, at least in animal models, leads to
long-lasting (several weeks) gene expression. In our opinion, clinical beneﬁt of gene
therapy can only be assessed if gene expression is maintained over several months
and we are, therefore, preparing for a multi-dose clinical study designed to run for
12 months with monthly administration of GL67/DNA complexes or placebo (n = 50
subjects/group). Preparation for the multi-dose trial involves validation of novel
and established biomarkers as endpoint assays, identiﬁcation of criteria for patient
selection and importantly a single dose pilot trial to assess safety and duration
of gene expression in human. While the work-up for the clinical programme with
GL67 is moving forward, Consortium scientist are developing Wave 2 products in
an attempt to further improve gene transfer to the airway epithelium. Although most
viral vectors are not suitable for repeat dose clinical trials, lentiviral vectors are a
notable exception and may be suitable for CF gene therapy. Our pre-clinical data
using a F/HN-pseudotyped simian immunodeﬁciency virus-derived vector shows
that single administration leads to efﬁcient gene expression for up to 12 months
and, importantly, appears to be allow repeat administration. A summary of the pre-
clinical and clinical work currently carried out within the UK CF Gene Therapy
Consortium will be presented.
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Cystic ﬁbrosis (CF) is caused by mutations in the cystic ﬁbrosis transmembrane
conductance regulator (CFTR), a Cl− channel with complex regulation that plays an
essential role in ﬂuid and electrolyte transport across epithelia. CFTR is assembled
from ﬁve domains: two membrane-spanning domains that form an anion-selective
pore, two nucleotide-binding domains (NBDs) that control channel gating and a
unique regulatory domain phosphorylation of which is a prerequisite for channel
activity.
By far the most common CF mutation is F508del, the deletion of a phenylalanine
residue at position 508 of the CFTR sequence. This mutation accounts for about
70% of CF mutations worldwide and is associated with a severe disease phenotype.
The F508del mutation disrupts the expression and function of CFTR in at least
three different ways. First and foremost, deletion of F508 causes misfolding of
CFTR protein, leading to the retention of the vast majority of the mutant protein
in the ER and its degradation by the proteasome. Second, decreased stability of
F508del-CFTR protein at the cell surface. Any F508del-CFTR that reaches the
apical membrane resides there for only a fraction of the time of wild-type CFTR.
Third, altered channel gating. F508del-CFTR Cl− channels exhibit a profound defect
in channel gating characterised by infrequent bursts of channel openings separated
by long closures of prolonged duration compared to those of wild-type CFTR.
Restoration of channel function to F508del-CFTR requires a drug to deliver the
mutant protein to the apical membrane (termed a CFTR corrector) and a drug to
rescue defective channel gating (termed a CFTR potentiator). A number of small
molecules have been identiﬁed (e.g. VRT-325 and Corr-4a) that rescue the cell
surface expression of F508del-CFTR [1,2]. Of note, VRT-325 and Corr-4a also
enhance the stability of F508del-CFTR at the apical membrane of CF epithelia [3].
A large number of small molecules have been identiﬁed (e.g. VRT-532), which act
as CFTR potentiators, rescuing the gating defect of F508del-CFTR [1]. Many of
these agents interact directly with the NBDs of CFTR to promote, and stabilise,
the formation of an NBD dimer, which controls channel gating. This presentation
will highlight how knowledge of the molecular pharmacology of CFTR is leading
to the development of new treatments for CF.
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The European CF Registry project aims to unite cystic ﬁbrosis data collection
across continents. The project has received support from the European Commission
(Framework 6, EuroCareCF, work package 2) which runs from 2006−9. The core
objective is to create a common data structure between the United States and Europe
for use by European CF Centres and after the project is complete, it is planned to
use this structure to analyse the comparative demographics of CF. Our partners
include the Cystic Fibrosis Foundation of the United States who have supplied
their software (Port CF) for all participating European CF centres together with the
European CF Society (ECFS) who have supplied their data handling expertise and
logistic support. EuroCareCF work package 2 aims to provide solutions to the key
ethical, legal, practical, data protection and social hurdles that must be overcome
as described on our web site (www.eurocarecf.eu).
Methodology is described on the web site. Crucially, the design is such that a
CF centre based approach to collect the data maintains anonymity whilst enabling
countries to compile their own aggregate country speciﬁc reports with the express
consent of each CF Centre.
